Sansure Biotech Inc.
SSE:688289.SS
20.25 (CNY) • At close June 10, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|
| Revenue
| 1,458.062 | 1,007.119 | 6,450.357 | 4,514.539 | 4,762.964 | 365.389 | 303.446 | 224.597 |
| Cost of Revenue
| 322.055 | 286.641 | 2,655.368 | 1,279.045 | 969.953 | 127.31 | 126.046 | 112.717 |
| Gross Profit
| 1,136.007 | 720.478 | 3,794.989 | 3,235.494 | 3,793.011 | 238.079 | 177.4 | 111.88 |
| Gross Profit Ratio
| 0.779 | 0.715 | 0.588 | 0.717 | 0.796 | 0.652 | 0.585 | 0.498 |
| Reseach & Development Expenses
| 0 | 196.276 | 331.834 | 187.504 | 82.771 | 38.954 | 35.682 | 27.639 |
| General & Administrative Expenses
| 0 | 13.93 | 102.631 | 42.569 | 38.728 | 11.884 | 9.859 | 11.323 |
| Selling & Marketing Expenses
| 0 | 192.383 | 732.229 | 392.328 | 519.805 | 123.093 | 99.31 | 69.96 |
| SG&A
| 347.945 | 206.312 | 834.86 | 434.897 | 558.532 | 134.976 | 109.169 | 81.283 |
| Other Expenses
| 510.285 | -109.573 | 95.457 | 44.499 | 39.573 | 14.731 | -1.015 | 30.359 |
| Operating Expenses
| 858.23 | 298.692 | 1,262.15 | 666.9 | 680.876 | 188.662 | 163.744 | 127.112 |
| Operating Income
| 277.777 | 427.463 | 2,339.809 | 2,621.786 | 3,086.031 | 47.516 | 11.704 | -27.73 |
| Operating Income Ratio
| 0.191 | 0.424 | 0.363 | 0.581 | 0.648 | 0.13 | 0.039 | -0.123 |
| Total Other Income Expenses Net
| -17.166 | -16.985 | -23.888 | -5.581 | -15.871 | -2.056 | -1.015 | 30.359 |
| Income Before Tax
| 260.611 | 410.478 | 2,315.922 | 2,616.205 | 3,070.161 | 45.46 | 10.689 | 2.629 |
| Income Before Tax Ratio
| 0.179 | 0.408 | 0.359 | 0.58 | 0.645 | 0.124 | 0.035 | 0.012 |
| Income Tax Expense
| 34.338 | 62.311 | 379.215 | 373.682 | 453.564 | 5.982 | 3.927 | 13.282 |
| Net Income
| 275.596 | 363.721 | 1,936.801 | 2,242.696 | 2,616.597 | 39.479 | 6.762 | -10.653 |
| Net Income Ratio
| 0.189 | 0.361 | 0.3 | 0.497 | 0.549 | 0.108 | 0.022 | -0.047 |
| EPS
| 0.44 | 0.62 | 3.35 | 3.79 | 4.42 | 0.067 | 0.019 | -0.03 |
| EPS Diluted
| 0.44 | 0.62 | 3.35 | 3.79 | 4.42 | 0.067 | 0.019 | -0.03 |
| EBITDA
| 430.476 | 574.933 | 2,436.374 | 2,670.976 | 3,099.825 | 68.623 | 32.462 | 39.683 |
| EBITDA Ratio
| 0.295 | 0.571 | 0.378 | 0.592 | 0.651 | 0.188 | 0.107 | 0.177 |